MedTrace Logo

Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

NCT01245231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2016-05-18

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.

Conditions

Interventions

GENETIC

protein expression analysis

GENETIC

western blotting

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

OTHER

medical chart review

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Michele S. Redell, MD, PhD · Texas Children's Cancer Center

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245231 on ClinicalTrials.gov